Advertisement

Role of Tumour Cell Eicosanoids and Membrane Glycoproteins IRGPIb and IRGPIIb/IIIa in Metastasis

  • K. V. Honn
  • I. M. Grossi
  • H. Chopra
  • B. W. Steinert
  • J. M. Onoda
  • K. K. Nelson
  • J. D. Taylor

Abstract

Eicosanoids are a group of oxygenated arachidonic acid metabolites which include Prostaglandins, thromboxanes, leukotrienes, lipoxins, and various hydroperoxy and hydroxy fatty acids. Eicosanoids are implicated in diverse cellular functions such as Chemotaxis, proliferation, cell-cell signaling etc. The first committed step in the biosynthesis of each of the eicosanoids, the incorporation of molecular oxygen into polyunsaturated fatty acids, is catalyzed by one of a group of enzymes calles fatty acid oxygenases. This group includes the cyclooxygenase (COX) of Prostaglandin endoperoxide synthase (PGH) and various lipoxygenases (LOX).

Keywords

Platelet Glycoprotein Tumour Cell Adhesion MS751 Cell Eicosanoid Metabolism Subendothelial Matrix 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Batchev AC, Riser DL, Hellner EG, Fliegiel SEG, Varani J (1986) Phorbol ester binding and phorbol ester-induced arachidonic acid metabolism in a highly responsive murine fibrosarcoma cell line and in a less-responsive variant. Clin Exptl Metastasis 4:51–61CrossRefGoogle Scholar
  2. Cavanaugh PG, Sloane BF, Bajkowski AS, Taylor JD, and Honn KV (1985) Purification and characterization of platelet aggregating activity from tumor cells: copurification with procoagulation activity. Thromb Res 37:309–326PubMedCrossRefGoogle Scholar
  3. Cavanaugh PG, Sloane BF, Honn KV (1988) Role of coagulation system in tumour cell induced platelet aggregation and metastasis. Hemostasis (in press)Google Scholar
  4. Chang YS, Fitzgerald LA, Grossi IM, Sundram U, Murray JA, Honn KV (1988) Tumour cell expression of mRNAs coding for the integrin receptors. FASEB J 2: A1406Google Scholar
  5. Charo IF, Fitzgerald LA, Steiner B, Raol Jr., SC, Bekeart LS, Phillips DR (1986) Platelet glycoproteins IIb and IIIa: evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. Proc Natl Acad Sci USA 83:8351–8355PubMedCrossRefGoogle Scholar
  6. Chopra H, Hatfield JS, Chang YS, Grossi IM, Fitzgerald LA, O’Gara CY, Marnett LJ, Diglio CA, Taylor JD, Honn KV (1988) Role of tumour cell cytoskeleton and membrane glycoprotein IRGIIb/IIIa in platelet adhesion to tumour cell membrane and tumour cell induced platelet agregation. Cancer Res (in press)Google Scholar
  7. Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983) A murine monoclonal antibody completely blocks the binding of fibrinogen to platelets and produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 72:325–338PubMedCrossRefGoogle Scholar
  8. Drago JR, Al-Mondhiry HAB (1984) The effect of Prostaglandin modulators on prostate tumour growth and metastasis. Anticancer Res 4:391–394PubMedGoogle Scholar
  9. Estrada J, Nicolson GL (1984) Tumour cell-platelet aggregation does not correlate with metastatic potential of rat 13762 NF mammary adenocardinoma tumour cell clones. Int J Cancer 34:101–105PubMedCrossRefGoogle Scholar
  10. Fitzgerald LA, Charo IF, Phillips DR (1985) Human and bovine endothelial cells synthesize membrane proteins similar to human platelet glycoproteins IIb and IIIa. J Biol Chem 260:10893–10896PubMedGoogle Scholar
  11. Fitzgerald LA, Phillips DR (1988) Structure and function of platelet membrane glycoproteins. In: Kunicki TJ, George J (eds) Platelet immunology. Lippincott, Philadelphia (in press)Google Scholar
  12. Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61:46–52PubMedCrossRefGoogle Scholar
  13. Gasic GJ, Boettinger D, Catalfamo JL, Gasic TB, Stewart GJ (1978) Aggregation of platelets and cell membrane vesiculation by rat cells transformed in vitro by Rous sarcoma virus. Cancer Res 38:2950–2955PubMedGoogle Scholar
  14. George JN, Nurden AT, Phillips DR (1984) Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 311:1084–1098PubMedCrossRefGoogle Scholar
  15. Grossi IM, Fitzgerald LA, Kendall A, Taylor JD, Sloane BF, Honn KV (1987a) Inhibition of human tumour cell induced platelet aggregation by antibodies to platelet glycoproteins Ib and IIb/IIIa. Proc Soc Exp Biol Med 186:378–383PubMedGoogle Scholar
  16. Grossi IM, Honn KV, Sloane BF, Thompson J, Ohannesian D, Kendall A, Newcombe M (1987b) Role of platelet glycoproteins Ib and IIb/IIIa in tumour cell induced platelet aggregation and tumour cell adesion to extracellular matrix. Thromb Haemostas 58:507Google Scholar
  17. Grossi IM, Hatfield JS, Fitzgerald LA, Newcombe M, Taylor JD, Honn KV (1988) Role of glycoproteins immunologically related to Ib and IIb/IIIa in tumour cell-platelet and tumour cell-matrix interactions. FASEB J (in press)Google Scholar
  18. Hadjiagapiou C, Spector AA (1986) 12-Hydroxyeicosatetraenoic acid reduces prostacyclin production by endothelial cells. Prostaglandins 31:1135–1144PubMedCrossRefGoogle Scholar
  19. Honn KV (1983) Inhibition of tumour cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis 1:103–114PubMedCrossRefGoogle Scholar
  20. Honn KV, Dunn JR (1982) Nafazatrom (Bay g 6575) inhibition of tumour cell lipoxygenase activity and cellular proliferation. FEBS Lett 139:65–68PubMedCrossRefGoogle Scholar
  21. Honn KV, Cicone B, Skoff A (1981) Prostaxyclin: a potent antimetastatic agent. Science 212:1270–1272PubMedCrossRefGoogle Scholar
  22. Honn KV, Meyer J, Neagos G, Henderson T, Westley C, Tatanatharathorn V (1982) Control of tumour growth and metastasis with prostacyclin and thromboxane synthase inhibitors: evidence for a new antitumour and antimetastatic agent (Bay g 6575). In: Jamieson G (ed) Interactions of platelets and tumour cells. Liss, New York, pp 295–331Google Scholar
  23. Honn KV, Busse WD, Sloane BF (1983) Prostacyclin and thromboxanes. Implications for their role in tumour cell metastasis. Biochem Pharmacol 32:1–11PubMedCrossRefGoogle Scholar
  24. Honn KV, Menter DG, Onoda JM, Taylor JD, Sloane BF (1984) Role of prostacyclin as a natural deterrent to hematogenous tumour metastasis. In: Nicolson G, Milas L (eds) Cancer invasion metastasis. Raven, New York, pp 361–388Google Scholar
  25. Honn KV, Onoda JM, Menter DG, Taylor JD, Sloane BF (1985) Prostacyclin in the control of tumour metastasis. In: Cohen MM (ed) Biological protection with Prostaglandins, vol 1. CRC, Boca Raton, pp 91–110Google Scholar
  26. Honn KV, Steinert BW, Onoda JM, Sloane BF (1987a) The role of platelets in metastatis. Biorheology 24:127–137PubMedGoogle Scholar
  27. Honn KV, Steinert BW, Moin K, Onoda JM, Taylor JD, Sloane BF (1987b) The role of platelet cyclooxygenase and lipoxygenase in tumour cell induced platelet aggregation. Biochem Biopys Res Comm 145:384–389CrossRefGoogle Scholar
  28. Kieffer N, Debili N, Wicki A, Titeux M, Henri A, Michel Z, Gorius JB, Vainchanker W, Clemetson KJ (1986) Expression of platelet glycoproteins Ib-α in HEL cells. J Biol Chem 261:15854–15862PubMedGoogle Scholar
  29. Maniglia CA, Loulakis PP, Sartorelli AC (1986) Interference with tumour cell-induced degradation of endothelial matrix on the antimetastatic action of nafazatrom. J Natl Cancer Inst 76:739–744PubMedGoogle Scholar
  30. Marnett LJ, Siedlick PH, Ochs RC, Pagels WR, Daas M, Honn KV, Warnock RH, Tainer BE, Eling TE (1984) Mechanism of the stimulation of Prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Mol Pharmacol 26:328–335PubMedGoogle Scholar
  31. Mehta P (1984) Evidence for altered arachidonic acid metabolism in tumour metastasis. In: Honn KV, Sloane BF (eds) Hemostatic Mechanisms of Metastasis. Nijhoff, Boston, pp 233–243Google Scholar
  32. Mehta P, Springfield D, Ostrowski N (1983) Arterial proatacyclin generation is decreased in patients with malignant bone tumours. Cancer 52:1297–1300PubMedCrossRefGoogle Scholar
  33. Mehta P, Lawson D, Ward MB, Ambrose LL, Limura A (1986) Effects of thromboxane A2 inhibition of osteogenic sarcoma cell-induced platelet aggregation. Cancer Res 46:5061–5063PubMedGoogle Scholar
  34. Menter DG, Onoda JM, Taylor JD, Honn KV (1984) Effects of prostacyclin on tumour cell induced platelet aggregation. Cancer Res 44:450–456PubMedGoogle Scholar
  35. Menter DG, Steinert BW, Sloane BF, Gundlach N, O’Gara CY, Narnett LJ, Diglio CA, Walz D, Taylor JD, Honn KV (1987a) Role of platelet membrane in enhancement of tumour cell adhesion to endothelial cell extracellular matrix. Cancer Res 47:6751–6762PubMedGoogle Scholar
  36. Menter DG, Sloane BF, Steinert BW, Onoda J, Craig R, Harkins C, Taylor JD, Honn KV (1987b) Platelet enhancement of tumour cell adhesion to subendothelial matrix. Role of cytoskeleton and platelet membrane. J Natl Cancer Inst 79:1077–1090PubMedGoogle Scholar
  37. Menter DG, Harkins C, Onoda J, Riorden W, Sloane BF, Taylor JD, Honn KV (1987c) Inhibition of tumour cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. Invasion Metastasis 7:109–128PubMedGoogle Scholar
  38. Menter DG, Onoda JM, Moilanen D, Sloane BF, Taylor JD, Honn KV (1987d) Inhibition by prostacyclin of the tumour cell-induced platelet release reaction and platelet aggregation. J Natl. Cancer Inst 78:961–969PubMedGoogle Scholar
  39. Menter DG, Hatfield JS, Harkins C, Sloane BF, Taylor JD, Crissman JD, Honn KV (1987e) Tumour cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumour cells. Clin Expl Metastasis 5:65–78CrossRefGoogle Scholar
  40. Nurden AT, George JN, Phillips DR, 1986, Platelet membrane glycoproteins: their structure, function and modification in disease. In: Phillips DR, Schuman MS (eds) Biochemisty of platelets. Academic, Orlando pp 159–224CrossRefGoogle Scholar
  41. Onoda JM, Sloane BF, Honn KV (1984) Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors. Thromb Res 34:367–378PubMedCrossRefGoogle Scholar
  42. Onoda JM, Nelson KK, Grossi IM, Umbarger LA, Taylor JD, Honn KV (1988) Separation of high and low metastatic subpoppulations from solid tumours by centrifugal elutriation. Proc Soc Exp Biol Med 187:250–255PubMedGoogle Scholar
  43. Peterson DM, Stathopoulos NA, Georgio DD, Helums JD, Molke JL (1987) Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins IIb and IIIa. Blood 69:625–628PubMedGoogle Scholar
  44. Plow E, Ginsberg MH, Marguerie GA (1986) Expression and function of adhesive proteins on the platelet surface. In: Phillips DR, Schuman MS (eds) Biochemistry of platelets. Academic, Orlando, pp 225–256CrossRefGoogle Scholar
  45. Ruoslahti E, Pierschbacher MD (1987) New perspectives in cell adhesion: RGD and integrins. Science 238:491–497PubMedCrossRefGoogle Scholar
  46. Serneri GGN, Abbate R, Gensini GF, Panetta A, Coslo G, Costantini A, Carini M, Seloi C (1986) Altered 1-14C arachidonic acid metabolism in arterial wall from patients with renal cell carcinoma. J Urol 135:1071–1074Google Scholar
  47. Sloane BF, Honn KV (1985) Proteolytic enzymes and arachidonic acid metabolism. In: Lands WE (ed) Biochemistry of arachidonic acid metabolism. Nijhoff, Boston, pp 311–322CrossRefGoogle Scholar
  48. Sloane BF, Makim S, Dunn JR, Lacoste R, Theodorou M, Battista J, Alex R, Honn KV (1982) Lipoxygenase products as mediators of tumour cell lysosomal enzyme release: inhibition with nafazatrom. In: Powles TJ, Bockman RS, Honn KV, Ramwell P (eds) Prostaglandins and cancer. Liss, New York, pp 789–792Google Scholar
  49. Steinert BW, Grossi IM, Umbarger LA, Fitzgerald LA, Honn KV Role of platelet eicosanoid metabolism and membrane glycoproteins in tumour cell induced platelet aggregation. (submitted)Google Scholar
  50. Tabilio A, Rosa JP, Testa P, Kieffer U, Nurden N, DelCanizio AT, Breton-Gorius MT, Vainchenker W (1984) Expression of platelet membrane glycoproteins and α-granule proteins by a human erythroleukemia cell line (HEL). EMBO J 3:353–359Google Scholar
  51. Tanaka NG, Tohgo A, and Ogawa H (1986) Platelet-aggregating activities of metastasizing tumour cells. V. In situ roles of platelets in hematogenous metastasis. Invasion Metastasis 6:209–224PubMedGoogle Scholar
  52. Thiagarajan P, Shapiro S, Swererlitsch L, McCord S (1987) Human erythroleukemia cell line synthesizes a functionally active glycoprotein IIb/IIIa complex capable of binding fibrinogen. Biochem Biophys Acta 924:127–134PubMedCrossRefGoogle Scholar
  53. Tohgo A, Tanaka NG, Ogawa H (1986) Platelet aggregating activities of metastasizing tumour cells. IV. Effects of cell surface modification on thrombin generation, platelet aggregation ans dubsequent lung colonization. Invasion Metastasis 6:58–68PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • K. V. Honn
    • 2
    • 1
  • I. M. Grossi
    • 2
    • 1
  • H. Chopra
    • 2
    • 1
  • B. W. Steinert
    • 2
    • 1
  • J. M. Onoda
    • 2
    • 1
  • K. K. Nelson
    • 2
    • 1
  • J. D. Taylor
    • 2
    • 1
  1. 1.Gershenson Radiation Oncology CenterHarper Grace HospitalsDetroitUSA
  2. 2.Departments of Radiation Oncology and Biological SciencesWayne State UniversityUSA

Personalised recommendations